These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 28837942)

  • 21. [Selective serotonin reuptake inhibitors in treatment of compulsive symptoms within the scope of schizophrenia].
    Scholl HP; Kasper S; Danos P; Höflich G; Möller HJ
    Nervenarzt; 1994 Jul; 65(7):478-81. PubMed ID: 7800092
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder.
    Saxena S; Wang D; Bystritsky A; Baxter LR
    J Clin Psychiatry; 1996 Jul; 57(7):303-6. PubMed ID: 8666572
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness of fluoxetine on various subtypes of obsessive-compulsive disorder.
    Farnam A; Goreishizadeh MA; Farhang S
    Arch Iran Med; 2008 Sep; 11(5):522-5. PubMed ID: 18759519
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Augmentation with cognitive behavioural therapy has superior efficacy to augmentation with risperidone for treating adults with treatment-resistant OCD.
    O'Neill J
    Evid Based Ment Health; 2014 May; 17(2):58-9. PubMed ID: 24713316
    [No Abstract]   [Full Text] [Related]  

  • 25. Effects of tryptophan depletion on selective serotonin reuptake inhibitor-remitted patients with obsessive compulsive disorder.
    Hood SD; Broyd A; Robinson H; Lee J; Hudaib AR; Hince DA
    J Psychopharmacol; 2017 Dec; 31(12):1615-1623. PubMed ID: 29095069
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A case report of risperidone-induced obsessive-compulsive symptoms.
    Alzaid K; Jones BD
    J Clin Psychopharmacol; 1997 Feb; 17(1):58-9. PubMed ID: 9004062
    [No Abstract]   [Full Text] [Related]  

  • 27. A case of social phobia with obsessive-compulsive symptoms improved by paroxetine in combination with risperidone.
    Yamauchi K; Ohta K; Taniguchi T; Ohmori T
    Gen Hosp Psychiatry; 2004; 26(3):242-3. PubMed ID: 15121355
    [No Abstract]   [Full Text] [Related]  

  • 28. Adjunctive quetiapine for serotonin reuptake inhibitor-resistant obsessive-compulsive disorder: a meta-analysis of randomized controlled treatment trials.
    Fineberg NA; Stein DJ; Premkumar P; Carey P; Sivakumaran T; Vythilingum B; Seedat S; Westenberg H; Denys D
    Int Clin Psychopharmacol; 2006 Nov; 21(6):337-43. PubMed ID: 17012980
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: What moderates improvement?
    Wheaton MG; Rosenfield D; Foa EB; Simpson HB
    J Consult Clin Psychol; 2015 Oct; 83(5):926-937. PubMed ID: 26009783
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A systematic review of the use of risperidone, paliperidone and aripiprazole as augmenting agents for obsessive-compulsive disorder.
    Brakoulias V; Stockings E
    Expert Opin Pharmacother; 2019 Jan; 20(1):47-53. PubMed ID: 30360669
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An adolescent male with multiple paraphilias successfully treated with fluoxetine.
    Galli VB; Raute NJ; McConville BJ; McElroy SL
    J Child Adolesc Psychopharmacol; 1998; 8(3):195-7. PubMed ID: 9853694
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fluoxetine in the treatment of obsessive compulsive disorder.
    Fontaine R; Chouinard G
    Prog Neuropsychopharmacol Biol Psychiatry; 1985; 9(5-6):605-8. PubMed ID: 3878975
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder.
    Koran LM; Ringold AL; Elliott MA
    J Clin Psychiatry; 2000 Jul; 61(7):514-7. PubMed ID: 10937610
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fluoxetine versus phenelzine in obsessive-compulsive disorder.
    Golwyn DH; Sevlie CP
    Am J Psychiatry; 1999 Jan; 156(1):159-60. PubMed ID: 9892321
    [No Abstract]   [Full Text] [Related]  

  • 35. Plasma melatonin and cortisol circadian patterns in patients with obsessive-compulsive disorder before and after fluoxetine treatment.
    Monteleone P; Catapano F; Tortorella A; Di Martino S; Maj M
    Psychoneuroendocrinology; 1995; 20(7):763-70. PubMed ID: 8848522
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quetiapine addition in obsessive-compulsive disorder: is treatment outcome affected by type and dose of serotonin reuptake inhibitors?
    Denys D; Fineberg N; Carey PD; Stein DJ
    Biol Psychiatry; 2007 Feb; 61(3):412-4. PubMed ID: 17241831
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Obsessive-compulsive symptoms in clozapine-treated schizophrenic patients.
    Ertugrul A; Anil Yagcioglu AE; Eni N; Yazici KM
    Psychiatry Clin Neurosci; 2005 Apr; 59(2):219-22. PubMed ID: 15823172
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Group cognitive-behavioral therapy versus selective serotonin reuptake inhibitors for obsessive-compulsive disorder: a practical clinical trial.
    Belotto-Silva C; Diniz JB; Malavazzi DM; Valério C; Fossaluza V; Borcato S; Seixas AA; Morelli D; Miguel EC; Shavitt RG
    J Anxiety Disord; 2012 Jan; 26(1):25-31. PubMed ID: 21907540
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antipsychotic Augmentation of Serotonin Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder: An Update Meta-Analysis of Double-Blind, Randomized, Placebo-Controlled Trials.
    Dold M; Aigner M; Lanzenberger R; Kasper S
    Int J Neuropsychopharmacol; 2015 May; 18(9):. PubMed ID: 25939614
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A review of antipsychotics in the treatment of obsessive compulsive disorder.
    Fineberg NA; Gale TM; Sivakumaran T
    J Psychopharmacol; 2006 Jan; 20(1):97-103. PubMed ID: 16204331
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.